New Issue: Orbital Catastrophe Ahead? Read Now

Investigating Inflammation

Join Our Community of Science Lovers!

Image: University of Chicago Medical Center

The body's immune system is a formidable force. Upon detecting invaders, it launches a no-holds barred attack--the inflammatory response. But once it has the assailants under control, the immune system must reign in the inflammation it caused because, if left unregulated, it can do extensive tissue damage. According to a report published today in the journal Science, researchers have determined that a little-known molecule called A20 plays a key role in quelling inflammation. And the discovery could lead to new treatment for inflammatory diseases such as rheumatoid arthritis and ulcerative colitis.

Thinking that A20 was only produced in a few tissues, researchers at the University of Chicago originally set out to pinpoint A20's function in certain white blood cells in the intestine. In order to do that, they created a line of genetically altered mice that lacked the A20 gene. But a few weeks after birth, these so-called "knockout mice" spontaneously developed serious inflammation and tissue damage in several organs (see photo). Exposing them to inflammation-triggering substances led to septic-shock. Normal mice, in contrast, exhibited no symptoms, even when given 10-fold higher doses of the substances. "We found that A20 was absolutely essential for down-regulating the inflammatory response and averting the damage unrestrained inflammation can cause in multiple tissues," says team member Averil Ma.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Specifically A20 appears to call off a substance known as tumor necrosis factor (TNF). Though critical to the immune response, prolonged release of TNF leads to severe injury. Although the FDA has approved antibodies to TNF for the purposes of treating inflammatory disorders, Ma notes that "these therapies are not always effective." But the discovery of A20's crucial regulatory role should open up new therapeutic avenues. "We can now hope to block cellular responses to TNF," Ma remarks, "in addition to trying to block TNF itself."

Kate Wong is an award-winning science writer and was formerly senior editor for features at Scientific American, where she focused on evolution, ecology, anthropology, archaeology, paleontology and animal behavior. She is fascinated by human origins, which she has covered for nearly 30 years. Recently she has become obsessed with birds. Her reporting has taken her to caves in France and Croatia that Neandertals once called home to the shores of Kenya’s Lake Turkana in search of the oldest stone tools in the world, as well as to Madagascar on an expedition to unearth ancient mammals and dinosaurs, the icy waters of Antarctica, where humpback whales feast on krill, and a “Big Day” race around the state of Connecticut to find as many bird species as possible in 24 hours. Wong is co-author, with Donald Johanson, of Lucy’s Legacy: The Quest for Human Origins. She holds a bachelor of science degree in biological anthropology and zoology from the University of Michigan. Follow her on Bluesky @katewong.bsky.social

More by Kate Wong

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe